The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of atorvastatin for the treatment of adults with immune thrombocytopenia (ITP).
The investigators anticipate to undertaking a parallel group, single-centre, randomised controlled trial of 30 ITP adult patients, which have no indications of glucocorticoid therapy (platelets count \> 30\*10\^9/L )from Qilu Hospital of Shandong University in China.15 of the participants are randomly selected to receive atorvastatin in 20 mg/d combining with 10 mg/d for 6 months. Platelet count, bleeding and other symptoms were evaluated before and after treatment, adverse events are also recorded throughout the study in order to report the efficacy and safety of atorvastatin for the treatment of adults with ITP.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Atorvastatin will be given in 20 mg po qn for 1 month
Atorvastatin will be given in 10 mg po qn for 1 month
Dexamethasone will be given in 40mg po qd for 4 days
Qilu hospital, Shandong University
Jinan, Shandong, China
Evaluation of platelet response
Platelet count will be observed at 1 month, 3 months, 6 months and 12 months after atorvastatin therapy
Time frame: up to 1 year per subject
Therapy associated adverse events
The number and frequency of therapy associated adverse events
Time frame: up to 1 year per subject
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.